Efficacy and Safety of DLBS3233 in Prediabetic Patients

Prediabetic Clinical Trial

— DIPPER-DM  

Official title:

Phase III Clinical Study : DLBS3233 in Primary Prevention of Type 2 Diabetes Mellitus [DIPPER-DM]

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01531933
• Other study ID #: DLBS3233-0711
• Status: Completed
• Phase: Phase 3
• First received: February 9, 2012
• Last updated: August 6, 2012
• Start date: November 2011
• Est. completion date: July 2012

Study information

• Verified date: August 2012
• Source: Dexa Medica Group
• Contact: n/a
• Is FDA regulated: No
• Health authority: Indonesia: National Agency of Drug and Food Control
• Study type: Interventional

Clinical Trial Summary

This is a 2-arm, prospective, double blind, randomized, and controlled clinical study for 12 weeks of therapy to investigate clinical efficacy and safety of DLBS3233.

It is hypothesized that DLBS3233 will delay the progress of beta-cell dysfunction as measured by the improvement of prandial (particularly the first phase) insulin secretion as well as insulin resistance in prediabetic subjects which may prevent the conversion of prediabetes into type 2 diabetes mellitus.

Description:

There will be two groups of treatment in this study who will receive DLBS3233 or placebo of DLBS3233 for 12 weeks of therapy.

Subjects will be provided with an education on lifestyle modification given by the assigned nutritionist. All subjects will be advised to follow such a lifestyle modification throughout the study period.

All subjects will be under direct supervision of a medical doctor during the study period.

All clinical and laboratory examinations to evaluate the investigational drug's efficacy, will be performed at baseline, Week 8th and Week 12th (end) of study treatment. Blood glucose level (both FPG and 2h-PG) will be performed at baseline and at interval of 4 weeks over the 12 weeks of study treatment. Safety examinations will be performed at baseline and at the end of study. Occurrence of adverse event will be observed during the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: July 2012
• Est. primary completion date: July 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Male or female subjects with age of 18-60 years

• Prediabetic patients (2h-PPPG level of 140-199 mg/dL)

• Serum ALT = 2.5 times upper limit of normal

• Serum creatinine < 1.5 times upper limit of normal

• Able to take oral medication

Exclusion Criteria:

• Female of childbearing potential

• History of diabetes mellitus

• History of symptomatic coronary arterial disease, stroke, and cardiovascular events

• Current treatment with systemic corticosteroids or herbal (alternative) medicines

• Any other disease state or uncontrolled illness, which judged by the investigator, could interfere with trial participation or trial evaluation

• Participation in any other clinical studies within 30 days prior to screening

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Prediabetic
• Prediabetic State

Intervention

Drug:
• DLBS3233
For the first 4 weeks, subjects should take DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of < 140 mg/dL or a decrease of 2h-PG level of = 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.
• Placebo of DLBS3233
For the first 4 weeks, subjects should take placebo of DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of < 140 mg/dL or a decrease of 2h-PG level of = 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.

Locations

Country	Name	City	State
Indonesia	Department of Internal Medicine, dr. M. Djamil Padang Hospital	Padang	West Sumatera

Sponsors (1)

Lead Sponsor	Collaborator
Dexa Medica Group

Country where clinical trial is conducted

Indonesia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in 15-minute post prandial insulin level	Change in 15-minute post prandial insulin level from baseline to 12 weeks of treatment	12 weeks of treatment	No
Secondary	Change in 15-minute post prandial insulin level	Change in 15-minute post prandial insulin level from baseline to 8 weeks of treatment	8 weeks of treatment	No
Secondary	Change in 2-hour post prandial insulin level	Change in 2-hour post prandial insulin level from baseline to 8 weeks and to 12 weeks of treatment	8 weeks and 12 weeks of treatment	No
Secondary	Change in 15-minute post prandial plasma glucose	Change in 15-minute post prandial plasma glucose from baseline to 8 weeks and to 12 weeks of treatment	8 weeks and 12 weeks of treatment	No
Secondary	Change in 2-hour post prandial plasma glucose	Change in 2-hour post prandial plasma glucose from baseline to each study visit (4 weeks, 8 weeks, and 12 weeks of treatment)	4 weeks, 8 weeks, and 12 weeks of treatment	No
Secondary	Change in HOMA-IR	Change in HOMA-IR from baseline to 8 weeks and to 12 weeks of treatment	8 weeks and 12 weeks of treatment	No
Secondary	Change in hs-CRP	Change in hs-CRP from baseline to 8 weeks and to 12 weeks of treatment	8 weeks and 12 weeks of treatment	No
Secondary	Improvement in lipid profile	Improvement in lipid profile from baseline to 8 weeks and to 12 weeks of treatment, including: fasting plasma HDL-cholesterol, fasting plasma triglyceride, 15-minute post prandial plasma triglyceride, and 2-hour post prandial plasma triglyceride	8 weeks and 12 weeks of treatment	No
Secondary	Change in adiponectin	Change in adiponectin from baseline to 8 weeks and to 12 weeks of treatment	8 weeks and 12 weeks of treatment	No
Secondary	Change in waist-to-hip ratio	Change in waist-to-hip ratio from baseline to each of study visit (4 weeks, 8 weeks, and 12 weeks of treatment)	4 weeks, 8 weeks, and 12 weeks of treatment	No
Secondary	ECG	ECG will be evaluated at baseline and at end of study (12 weeks of treatment)	12 weeks of treatment	Yes
Secondary	Vital signs	Vital signs (systolic and diastolic blood pressure, heart rate, respiration rate) will be evaluated at baseline and at each study visit (4 weeks, 8 weeks, and 12 weeks of treatment)	4 weeks, 8 weeks, and 12 weeks of treatment	Yes
Secondary	Body weight	Body weight will be evaluated at baseline and at each study visit (4 weeks, 8 weeks, and 12 weeks of treatment)	4 weeks, 8 weeks, and 12 weeks of treatment	Yes
Secondary	Liver function	Liver function (levels of serum ALT, ?-GT, alkaline phosphatase) will be evaluated at baseline and at end of study (12 weeks of treatment)	12 weeks of treatment	Yes
Secondary	Renal function	Renal function (serum creatinine level) will be evaluated at baseline and at end of study (12 weeks of treatment)	12 weeks of treatment	Yes
Secondary	Adverse events	Adverse events as well as number of subjects experienced the events will be observed and evaluated during study period (12 weeks) and until all adverse events have been recovered or stabilized	1-12 weeks of treatment	Yes